LAUSR

The purpose of the study is to investigate the influence of sulfobutyl ether β-cyclodextrin (SBE_7-β-CD) on the bioavailability of valsartan. Phase solubility investigations showed an A_L type curve. The estimated apparent stability constant for valsartan SBE_7-β-CD is 427 ± 0.32 M^−1. Inclusion complexes of valsartan SBE_7-β-CD in equal molar ratio were prepared by microwave irradiation technique. The process parameters were optimised with a central composite face design. Response surface graphs and contour plots showed how process factors affected drug content. The inclusion complexes prepared by optimising process variables are characterised. The DSC and X-ray diffraction confirm the formation of inclusion complexes and the drug’s transition from a crystalline to an amorphous state. FTIR suggests hydrogen bonding between valsartan and SBE_7-β-CD. SEM showed changes in drug morphology and shape. The dissolution rate of the prepared SBE_7-β-CD complex using microwave irradiation was 2.85 times that of pure valsartan. The inclusion complex was formulated into tablet dosage forms F _1 to F _4. Furthermore, oral bioavailability studies in rats with tablet formulation F _3 were carried out and compared to the marketed Diovan® tablet as a reference standard. The F _3 tablet formulation exhibited significantly higher values of AUC_0-∞ and C _max than the reference. Finally, the microwave-irradiated valsartan SBE_7-β-CD inclusion complex converted into tablet dosage form may be a promising approach to increasing valsartan oral bioavailability.